Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4QYG

CHK1 kinase domain in complex with diazacarbazole compound 14

Summary for 4QYG
Entry DOI10.2210/pdb4qyg/pdb
Related4QYE 4QYF 4QYH
DescriptorSerine/threonine-protein kinase Chk1, 3-[4-(4-methylpiperazin-1-yl)phenyl]-9H-pyrrolo[2,3-b:5,4-c']dipyridine-6-carboxylic acid (3 entities in total)
Functional Keywordsprotein kinase, phosphotransfer catalyst, transferase-transferase inhibitor complex, transferase/transferase inhibitor
Biological sourceHomo sapiens (human)
Cellular locationNucleus: O14757
Total number of polymer chains2
Total formula weight69185.27
Authors
Wiesmann, C.,Wu, P. (deposition date: 2014-07-24, release date: 2014-12-17, Last modification date: 2024-02-28)
Primary citationGazzard, L.,Appleton, B.,Chapman, K.,Chen, H.,Clark, K.,Drobnick, J.,Goodacre, S.,Halladay, J.,Lyssikatos, J.,Schmidt, S.,Sideris, S.,Wiesmann, C.,Williams, K.,Wu, P.,Yen, I.,Malek, S.
Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1.
Bioorg.Med.Chem.Lett., 24:5704-5709, 2014
Cited by
PubMed Abstract: Checkpoint kinase 1 (ChK1) is activated in response to DNA damage, acting to temporarily block cell cycle progression and allow for DNA repair. It is envisaged that inhibition of ChK1 will sensitize tumor cells to treatment with DNA-damaging therapies, and may enhance the therapeutic window. High throughput screening identified carboxylate-containing diarylpyrazines as a prominent hit series, but with limited biochemical potency and no cellular activity. Through a series of SAR investigations and X-ray crystallographic analysis the critical role of polar contacts with conserved waters in the kinase back pocket was established. Structure-based design, guided by in silico modeling, transformed the series to better satisfy these contacts and the novel 1,7-diazacarbazole class of inhibitors was discovered. Here we present the genesis of this novel series and the identification of GNE-783, a potent, selective and orally bioavailable inhibitor of ChK1.
PubMed: 25453805
DOI: 10.1016/j.bmcl.2014.10.063
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.75 Å)
Structure validation

231029

數據於2025-02-05公開中

PDB statisticsPDBj update infoContact PDBjnumon